Skip to main content

Pharmaceutical Quality Control

December 19, 2024

Celebrating innovation with Professor Ding: A pioneer in sustainable endotoxin testing

A world-renowned pioneer in the field of molecular biotechnology and currently Emeritus Professor at the Department of Biological Sciences, National University of Singapore (NUS), Professor Jeak Ling Ding’s research focuses on innate immunity in host-pathogen interaction, antimicrobial defense and anticancer immunomodulation. Her work has resulted in around 300 scientific publications and patents, along with a host of awards and honors, including most recently her induction into the Singapore Women’s Hall of Fame. We spoke with Professor Ding to learn more about her career defining breakthrough to genetically engineer recombinant Factor C, and the importance of creating a sustainable and ethical alternative to replace traditional methods of endotoxin testing.
Discover More

  • June 19, 2024

    Recombinant Factor C Methods for Endotoxin Testing: Towards Sustainable Development and Reliable Supply Chain

    In 2020, vaccine research received significant attention as researchers were engaged in the race to develop an effective vaccine against SARS-CoV-2 worldwide. More broadly, the entire pharmaceutical industry is experiencing this rapid growth. In this context, supply chain sustainability is crucial. The use of horseshoe crab blood in the quality and safety control process is essential to ensure the safety of injectable and implantable pharmaceutical products. Environmental challenges are key in the debate around the use of traditional Limulus Amebocyte Lysate (LAL) methods in favor of more sustainable methods such as recombinant Factor C (rFC).
    Read more

  • March 26, 2024

    Precision matters: Navigating the landscape of quality control in biologics

    Humans have been using plant and animal derived products (biologics) to treat disease for thousands of years, but the advent of mass production in the 20th century enabled the growth of biologics as a recognized class of medicines. Unlike chemically derived medicines, which combine specific ingredients in an ordered process, biologics are typically very large, complex molecules or mixtures of molecules that are difficult to characterize.
    Read more

  • January 17, 2024

    Addressing Challenges in Expanding Access to Cell & Gene Therapies

    Cell and gene therapies have been undergoing exciting developments recently, including expansion into second line use for existing products. This means that cell and gene therapies are no longer treatments of last resort, and studies are currently underway for front line use.
    Read more

  • January 03, 2024

    Collaborative Research and Quality Control Supports Cell & Gene Therapy Development & Manufacturing

    The landscape of advanced therapy medicinal products (ATMPs) continues to evolve rapidly, revolutionizing modern medicine to help provide additional treatment options for patients with rare diseases, cancers, and autoimmune disorders.
    Read more